Ratan Capital Management LP Invests $777,000 in Thermo Fisher Scientific Inc. $TMO

Ratan Capital Management LP acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,550 shares of the medical research company’s stock, valued at approximately $777,000.

Other large investors have also recently modified their holdings of the company. Bank OZK bought a new stake in Thermo Fisher Scientific in the second quarter worth $1,096,000. Ausdal Financial Partners Inc. acquired a new stake in shares of Thermo Fisher Scientific in the second quarter worth about $456,000. North Dakota State Investment Board bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $7,505,000. BlackRock Inc. acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $15,501,867,000. Finally, German American Bancorp Inc. bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $4,920,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In other news, VP Lisa P. Britt sold 11,440 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares in the company, valued at approximately $9,064,366.08. The trade was a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares of the company’s stock, valued at $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 73,768 shares of company stock valued at $44,122,820. Corporate insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of several analyst reports. Morgan Stanley increased their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Piper Sandler lifted their target price on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a report on Monday, July 27th. Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Finally, Royal Bank Of Canada raised their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Trading Down 1.4%

Shares of TMO stock opened at $621.87 on Friday. The firm has a market capitalization of $229.94 billion, a P/E ratio of 33.45, a price-to-earnings-growth ratio of 2.57 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $647.00. The firm’s fifty day simple moving average is $558.64 and its 200 day simple moving average is $512.08. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the prior year, the firm earned $4.28 EPS. The business’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.